Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors

NCT06063681 is registered in ClinicalTrials.gov with Stingray Therapeutics as lead sponsor.

NCT NCT06063681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06063681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors
Lead sponsor
Stingray Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
October 12, 2023
Completion date
December 31, 2025
Enrollment
25 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced / metastatic solid tumor